The bar chart provides information about the amount of money, expressed in Sbn, that five large companies invest in medical study from 2012 to 2018 with a prediction till 2022. Overall, it is clear that there is an upward trend in all companies with according to forecast Novas spending the most money on research.
Pharm occupied the first place in investments on study approximately 9 Sbn which almost 3 time more that Avicenna spending (around 3Sbn) in 2012. It is followed by Fleming which waste around 5 Sbn but in 2018 it increased 2 times. A smaller investment on research was observed in Biopharma at about 1 Sbn and nearly 5 Sbn in 2018.
As regards projections, in 2022 Novas will spend around 57 Sbn, with such company will occupying the first place. It is observed that Biopharma investment will amount approximately
25 Sbn which consist of a half from Novas spending. Pharm spending will consist of 21 Sbn and it is a smaller share of money within all companies in 2022.
